BC Innovations | Aug 29, 2019
Distillery Techniques

The E3 ligase CHIP as an Alzheimer's disease biomarker

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Tissue markers; gene profiling Hippocampal expression levels of CHIP, an E3 ubiquition ligase, could serve as a biomarker of AD severity. High levels of a tau (microtubule-associated protein tau; MAPT; FTDP-17)...
BC Innovations | Jul 19, 2012
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD); Huntington's disease (HD) Caspase-6 (CASP6; MCH2) In vitro and cell culture studies identified a peptide-based inhibitor of CASP6,...
BC Innovations | Jun 30, 2011
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Stroke Caspase-6 (CASP6; MCH2); CASP9 (MCH6) In vitro and rodent studies suggest inhibiting CASP9 or CASP6 after stroke could improve outcomes. In a rat stroke...
BC Innovations | Jan 6, 2011
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Huntington's disease (HD) Caspase-3 (CASP3; CPP32); caspase-6 (CASP6; MCH2); huntingtin (HTT) A study in cell culture identified small molecule dual CASP3 and CASP6 inhibitors that...
BC Innovations | Nov 12, 2009
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Procaspase-3; procaspase-6; caspase-3 (CASP3; CPP32); caspase-6 (CASP6; MCH2) Studies in cell culture suggest that small molecule activators of procaspases could help treat cancer. High...
BC Innovations | Apr 16, 2009
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Huntington's disease (HD) Caspase-6 apoptosis-related cysteine peptidase (CASP6; MCH2) In vitro studies identified sulfonamide isatin Michael acceptor (IMA) analogs that could...
BC Innovations | Feb 26, 2009
Cover Story

Genentech's new parADigm

A study by a team at Genentech Inc. proposes a new mechanism for Alzheimer's disease pathogenesis by outlining a process that could be an early step in the neurodegenerative disorder. 1 The work also identifies...
BC Innovations | Feb 26, 2009
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/ marker/ pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Tumor necrosis factor receptor superfamily, member 21 (TNFRSF21; DR6); caspase-6 apoptosis-related cysteine peptidase (CASP6; MCH2); amyloid...
Items per page:
1 - 8 of 8